1. Home
  2. |Insights
  3. |DOJ Announces $3B in False Claims Act Recoveries

DOJ Announces $3B in False Claims Act Recoveries

Client Alert | 1 min read | 01.10.20

The Department of Justice announced that it recovered more than $3 billion in settlements and judgments from False Claims Act matters in Fiscal Year 2019. The release may be found here. In addition to describing in detail significant cases, the press release covers:

  • $2.6 billion in healthcare related recoveries
  • 633 qui tam suits filed
  • Research and grant misconduct by universities leading to more than $100 million in settlements
  • Penalties and damages imposed against individuals/company executives

This annual press release is an important tool for companies to understand FCA enforcement trends. Among other things, the press release offers a broad window into the state of False Claims Act risks and provides an opportunity for companies to review their compliance programs and address emerging issues or gaps that may exist.

For more information, join Crowell & Moring lawyers for a webinar discussing emerging False Claims Act risks for 2020 and beyond on Wednesday, January 15 from 1-2:30pm eastern. Registration is available here.

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights